Vanguard Fiduciary Trust
XENE icon

Vanguard Fiduciary Trust’s Xenon Pharmaceuticals XENE Stock Holding History

Vanguard Fiduciary Trust’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.61M Buy
92,878
+17,761
+24% +$986K ﹤0.01% 2106
2026
Q1 		$4.37M Buy
+75,117
New +$3.46M ﹤0.01% 2153

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Fiduciary Trust's XENE Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Xenon Pharmaceuticals (XENE) stake by 24% in Q2 2026, buying an estimated $986K and bringing the position to 92,878 shares worth $5.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2106.

Vanguard Fiduciary Trust first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 314 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Vanguard Fiduciary Trust held 92,878 shares of Xenon Pharmaceuticals worth $5.61M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 17,761 Xenon Pharmaceuticals shares in Q2 2026, an estimated $986K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2106 holding.
  • Vanguard Fiduciary Trust first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 314 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.